CING

Cingulate Inc. 10-Q Summary: Quarter Ended June 30, 2026

Business Context and Reporting Period

Cingulate Inc. is a biopharmaceutical company developing once-daily, multi-dose tablet therapies for ADHD and anxiety using its Precision Timed Release (PTR) platform. The lead asset, CTx-1301 (dexmethylphenidate), is in late-stage development. This report covers the quarterly period ended June 30, 2026. The Company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the six months ended June 30, 2026, increased by 71.8% compared to the same period in 2025, driven primarily by a surge in Selling, General, and Administrative (SG&A) expenses.
• SG&A Expansion: SG&A expenses rose 181.7% year-over-year (from $3.43 million to $9.67 million) due to pre-commercialization costs, including market access, pricing, and medical affairs activities in preparation for a potential CTx-1301 launch.
• R&D Decrease: Research and Development expenses decreased 25.4% year-over-year (from $4.92 million to $3.67 million) as clinical operations costs declined following the conclusion of Phase 3 trials, partially offset by increased manufacturing costs.
• Capital Raising: The Company significantly increased liquidity through a $12.0 million Private Placement in February 2026 and active sales under At-The-Market (ATM) and Lincoln Park Purchase Agreements, resulting in a net cash increase of $17.45 million for the six-month period.

Guidance, Outlook, and Risks

• Regulatory Status (Critical): On June 2, 2026, the FDA issued a Complete Response Letter (CRL) for the CTx-1301 New Drug Application (NDA). The CRL requested additional Chemistry, Manufacturing, and Controls (CMC) information but did not raise concerns regarding clinical safety or efficacy. The Company is working with its CDMO, Bend Bioscience, to address these deficiencies for resubmission.
• Liquidity Outlook: Management believes current cash resources ($28.4 million) are sufficient to fund operations into mid-2027, covering CMC work and commercial launch preparations. However, the filing includes a "substantial doubt" going concern warning due to the need for additional capital to sustain operations beyond that period.
• Commercial Readiness: The Company has signed agreements with Prasco, LLC for distribution and Indegene, Inc. for commercialization services, positioning for a rapid launch if approval is obtained.
• Risk Factors: Key risks include the potential delay or denial of FDA approval following the CRL, reliance on a single CDMO (Bend Bioscience) which received a Form 483 observation during a pre-approval inspection, and the need for continued capital raises which may result in shareholder dilution.

Investor Verification Checklist

• CMC Remediation Plan: Verify the specific timeline and costs associated with addressing the FDA's CMC requests in the CRL.
• CDMO Compliance: Monitor the status of the Form 483 observations issued to Bend Bioscience and the outcome of any potential FDA re-inspection.
• Cash Burn Rate: Assess the sustainability of the current cash position ($28.4 million) against the projected burn rate, particularly given the increased SG&A spend for commercial readiness.
• Dilution Impact: Review the terms of the 2025 Lincoln Park Purchase Agreement and the 2026 ATM Agreement to understand potential future equity dilution.
• Debt Obligations: Confirm the status of the 2025 Note with Avondale Capital, including redemption schedules and potential conversion to equity.